<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03295110</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0706</org_study_id>
    <nct_id>NCT03295110</nct_id>
  </id_info>
  <brief_title>Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases</brief_title>
  <acronym>Lili smart</acronym>
  <official_title>Lili Smart Study - Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lili smart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease and related diseases (ADRD) are a major public health issue. In France,&#xD;
      nearly 900,000 people have ADRD, which represents about 70% of dementia cases, and the&#xD;
      expected prevalence for 2020 is 1.2 million.&#xD;
&#xD;
      Patients with ADRD have cognitive, behavioral and functional impairments that lead to&#xD;
      progressive impairment of quality of life and autonomy. Maintaining them at home depends&#xD;
      predominantly on their caregivers, mainly family, spouse or child. By definition, the&#xD;
      caregiver is &quot;the person who provides partial or total support to an elderly dependent person&#xD;
      or a person with a disability in the vicinity of the victim for the activities of daily&#xD;
      life&quot;.&#xD;
&#xD;
      The investment of caregivers is therefore both human and financial, representing a greater or&#xD;
      lesser burden. This burden can significantly affect their quality of life. Indeed, studies&#xD;
      have shown that caregivers suffer from depletion, anxiety, depression and sleep disorders&#xD;
      resulting in a deterioration of their health, leading them to greater care consumption. They&#xD;
      would be more prone to cardiovascular diseases and cancer.&#xD;
&#xD;
      A review of the literature from 2009 examined 66 studies evaluating the contribution of&#xD;
      various technologies targeting demented patients and their caregivers. Of these, only 10&#xD;
      dealt with independence at home and the well-being of the patient and his / her caregiver.&#xD;
      The main limitations of these studies are the small samples (ranging from 1 to 6 patients),&#xD;
      the degree of cognitive degradation (mainly moderately severe) and the lack of standardized&#xD;
      assessment.&#xD;
&#xD;
      Although new technologies promise powerful home-based solutions, studies evaluating their&#xD;
      efficacy for patients with ADRD and their caregivers remain scarce and fragile at the level&#xD;
      of evidence due to methodological biases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Description of the intervention: Lili Smart solution consists of an application for&#xD;
      caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different&#xD;
      locations of the patient's home and a support service 24 / 24 and 7/7.&#xD;
&#xD;
      Objectives: The main objective is to evaluate the impact of the Lili Smart solution on the&#xD;
      burden felt by caregivers of patients with ADRD at 3 months and at 6 months of follow-up.&#xD;
&#xD;
      The secondary objectives are to evaluate the impact of the Lili Smart solution at 3 months&#xD;
      and 6 months of follow-up on:&#xD;
&#xD;
        -  The anxiety of the caregiver of the patient with ADRD;&#xD;
&#xD;
        -  Depression of the caregiver of the patient with ADRD;&#xD;
&#xD;
        -  The quality of life of the caregiver of the patient with ADRD;&#xD;
&#xD;
        -  The quality of life of the patient with ADRD,&#xD;
&#xD;
        -  The level of functional autonomy of the patient with ADRD.&#xD;
&#xD;
        -  The risks associated with the functional decline (falls, run aways) of the patient with&#xD;
           ADRD.&#xD;
&#xD;
      In addition to the social impact measurement, the study aims to demonstrate the&#xD;
      medico-economic impact of Lili smart solution as follow:&#xD;
&#xD;
        -  The direct and indirect medical costs of the patient and the caregiver.&#xD;
&#xD;
      Patient and caregiver adherence to the Lili Smart solution will also be assessed as a&#xD;
      secondary objective.&#xD;
&#xD;
      Methodology : This study is an interventional research on the human person meeting the&#xD;
      definition 1 ° of article L1121-1 of the CSP and not relating to the products mentioned in&#xD;
      article L. 5311-1 It is a randomized, controlled, single-blind, parallel-group,&#xD;
      interventional, randomized, controlled trial in N = 60 patients and their primary caregiver&#xD;
      with an observational phase (inactive device), and one interventional phase (activated&#xD;
      device).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Caregiver's burden evolution</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Natural caregiver's burden evolution after 6 months of follow-up. Natural caregiver's burden evolution after 6 months of follow-up. Assessement with the Zarit scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of the caregiver's anxiety level</measure>
    <time_frame>3 months and 6 months after randomization</time_frame>
    <description>Evolution of the caregiver's anxiety level estimated with repeated measures with the Spielberger's State-Trait Anxiety Inventory (STAI Y-A / Y-B).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the caregiver's depressive symptomatology</measure>
    <time_frame>3 months and 6 months after randomization</time_frame>
    <description>Evolution of the caregiver's depressive symptomatology estimated with repeated measures of the Beck Depression Inventory (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the caregiver's quality of life</measure>
    <time_frame>3 months and 6 months after randomization</time_frame>
    <description>Evolution of the caregiver's quality of life estimated with repeated measures of the Quality of Life in Alzheilmer's Disease scale, caregiver version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the patient's quality of life</measure>
    <time_frame>3 months and 6 months after randomization</time_frame>
    <description>Evolution of patient's quality of life estimated with repeated measures of the Quality of Life in Alzheilmer's Disease scale, patient version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the patient's independence</measure>
    <time_frame>3 months and 6 months after randomization</time_frame>
    <description>Evolution of the patient's independence with repeated measures of the Instrumental Activities of Daily Life (IADL-E, 9 items).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the caregiver's quality of life</measure>
    <time_frame>3 months and 6 months after randomization</time_frame>
    <description>Evolution of the caregiver's quality of life estimated with repeated measures of the Quality of Life with EQ-5D questionnaire (EuroQol Five Dimensions questionnaire).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the patient's quality of life</measure>
    <time_frame>3 months and 6 months after randomization</time_frame>
    <description>Evolution of patient's quality of life estimated with repeated measures of the Quality of Life with EQ-5D questionnaire (EuroQol Five Dimensions questionnaire).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of falls</measure>
    <time_frame>1 months, 3 months and 6 months after randomization</time_frame>
    <description>Number of times the patient has fallen after 1 month, 3 months and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of run aways</measure>
    <time_frame>1 months, 3 months and 6 months after randomization</time_frame>
    <description>Number of times the patient has ran away after 1 month, 3 months and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drugs prescribed to the caregiver and the patient</measure>
    <time_frame>at inclusion and at 6 months</time_frame>
    <description>Evolution of the number of drugs prescribed to the caregiver and the patient at inclusion and after 6 months of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect medical costs and direct non-medical costs</measure>
    <time_frame>6 months</time_frame>
    <description>Data for indirect medical costs and direct non-medical costs will be collected with the RUD LITE questionnaire and the Lyon CMRR's MEMORA database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the caregiver's adherence to the Lili Smart solution</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluation of the caregiver's adherence to the Lili Smart solution after 7 months of follow-up (1 month of observation phase then 6 months of intervention) estimated through data collected in Lili Smart databases (number of connections to the application).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of patient's adherence to the Lili Smart solution</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluation of the patient's adherence to the Lili Smart solution after 7 months of follow-up (1 month of observation phase then 6 months of intervention) estimated through data collected in Lili Smart databases (number of hours when the watch is worn).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver's burden evolution</measure>
    <time_frame>3 months after randomization</time_frame>
    <description>Natural caregiver's burden evolution after 3 months of follow-up. Assessement with the Zarit scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Functionalities of the Lili Smart Solution activated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Functionalities of the Lili Smart Solution non activated</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functionalities of the Lili Smart Solution activated</intervention_name>
    <description>Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.</description>
    <arm_group_label>Functionalities of the Lili Smart Solution activated</arm_group_label>
    <other_name>Non-medical connected device (Lili Smart solution) with active functionalities</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Functionalities of the Lili Smart Solution non activated</intervention_name>
    <description>Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.</description>
    <arm_group_label>Functionalities of the Lili Smart Solution non activated</arm_group_label>
    <other_name>Non-medical connected device (Lili Smart solution) with inactive functionalities</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Caregiver inclusion's criteria :&#xD;
&#xD;
          -  Natural caregiver helping the patient at least 6h / week for activities of daily&#xD;
             living (if more than one caregiver, only one &quot;referent&quot; caregiver will be involved);&#xD;
&#xD;
          -  Can be the caregiver of only one patient of the study.&#xD;
&#xD;
          -  Having the ability to follow the study at the discretion of the investigator;&#xD;
&#xD;
          -  Having agreed to participate in the study;&#xD;
&#xD;
          -  Affiliated to a social security scheme;&#xD;
&#xD;
        Patient Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Alzheimer's disease or related disease;&#xD;
&#xD;
          -  Living at home&#xD;
&#xD;
          -  Age ≥ 50 years&#xD;
&#xD;
          -  Mini Mental State Examination (MMSE): 16-24 (included) (light to moderate);&#xD;
&#xD;
          -  Affiliated to a social security scheme;&#xD;
&#xD;
          -  Having agreed to participate in the study;&#xD;
&#xD;
          -  Having the physical and psychic abilities to follow the study according to the&#xD;
             appreciation of the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients exclusion's criteria:&#xD;
&#xD;
          -  Known psychiatric disorders&#xD;
&#xD;
          -  Disabling motor and / or sensory impairment&#xD;
&#xD;
          -  Patient under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Krolak-Salmon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Viricel</last_name>
    <phone>4 72 43 25 01</phone>
    <phone_ext>+33</phone_ext>
    <email>deborah.viricel@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Romain Bachelet</last_name>
    <phone>4 72 43 22 25</phone>
    <phone_ext>+33</phone_ext>
    <email>romain.bachelet@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital des Charpennes</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Krolak Salmon, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 12, 2017</study_first_submitted>
  <study_first_submitted_qc>September 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease and Related Disorders (ADRD)</keyword>
  <keyword>natural caregiver</keyword>
  <keyword>non-medical connected device</keyword>
  <keyword>caregiver's burden</keyword>
  <keyword>anxiety</keyword>
  <keyword>costs</keyword>
  <keyword>quality of life</keyword>
  <keyword>depressive symptoms</keyword>
  <keyword>independence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03295110
org study id: 69HCL16_0706
nct id: NCT03295110
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Alzheimer's disease and related diseases (ADRD) are a major public health issue. In France,
      nearly 900,000 people have ADRD, which represents about 70% of dementia cases, and the
      expected prevalence for 2020 is 1.2 million.

      Patients with ADRD have cognitive, behavioral and functional impairments that lead to
      progressive impairment of quality of life and autonomy. Maintaining them at home depends
      predominantly on their caregivers, mainly family, spouse or child. By definition, the
      caregiver is "the person who provides partial or total support to an elderly dependent person
      or a person with a disability in the vicinity of the victim for the activities of daily
      life".

      The investment of caregivers is therefore both human and financial, representing a greater or
      lesser burden. This burden can significantly affect their quality of life. Indeed, studies
      have shown that caregivers suffer from depletion, anxiety, depression and sleep disorders
      resulting in a deterioration of their health, leading them to greater care consumption. They
      would be more prone to cardiovascular diseases and cancer.

      A review of the literature from 2009 examined 66 studies evaluating the contribution of
      various technologies targeting demented patients and their caregivers. Of these, only 10
      dealt with independence at home and the well-being of the patient and his / her caregiver.
      The main limitations of these studies are the small samples (ranging from 1 to 6 patients),
      the degree of cognitive degradation (mainly moderately severe) and the lack of standardized
      assessment.

      Although new technologies promise powerful home-based solutions, studies evaluating their
      efficacy for patients with ADRD and their caregivers remain scarce and fragile at the level
      of evidence due to methodological biases.
Description of the intervention: Lili Smart solution consists of an application for
      caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different
      locations of the patient's home and a support service 24 / 24 and 7/7.

      Objectives: The main objective is to evaluate the impact of the Lili Smart solution on the
      burden felt by caregivers of patients with ADRD at 3 months and at 6 months of follow-up.

      The secondary objectives are to evaluate the impact of the Lili Smart solution at 3 months
      and 6 months of follow-up on:

        -  The anxiety of the caregiver of the patient with ADRD;

        -  Depression of the caregiver of the patient with ADRD;

        -  The quality of life of the caregiver of the patient with ADRD;

        -  The quality of life of the patient with ADRD,

        -  The level of functional autonomy of the patient with ADRD.

        -  The risks associated with the functional decline (falls, run aways) of the patient with
           ADRD.

      In addition to the social impact measurement, the study aims to demonstrate the
      medico-economic impact of Lili smart solution as follow:

        -  The direct and indirect medical costs of the patient and the caregiver.

      Patient and caregiver adherence to the Lili Smart solution will also be assessed as a
      secondary objective.

      Methodology : This study is an interventional research on the human person meeting the
      definition 1 ° of article L1121-1 of the CSP and not relating to the products mentioned in
      article L. 5311-1 It is a randomized, controlled, single-blind, parallel-group,
      interventional, randomized, controlled trial in N = 60 patients and their primary caregiver
      with an observational phase (inactive device), and one interventional phase (activated
      device).
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Single (Outcomes Assessor)
measure: Caregiver's burden evolution
time frame: 6 months after randomization
description: Natural caregiver's burden evolution after 6 months of follow-up. Natural caregiver's burden evolution after 6 months of follow-up. Assessement with the Zarit scale
measure: Evolution of the caregiver's anxiety level
time frame: 3 months and 6 months after randomization
description: Evolution of the caregiver's anxiety level estimated with repeated measures with the Spielberger's State-Trait Anxiety Inventory (STAI Y-A / Y-B).
measure: Evolution of the caregiver's depressive symptomatology
time frame: 3 months and 6 months after randomization
description: Evolution of the caregiver's depressive symptomatology estimated with repeated measures of the Beck Depression Inventory (BDI)
measure: Evolution of the caregiver's quality of life
time frame: 3 months and 6 months after randomization
description: Evolution of the caregiver's quality of life estimated with repeated measures of the Quality of Life in Alzheilmer's Disease scale, caregiver version
measure: Evolution of the patient's quality of life
time frame: 3 months and 6 months after randomization
description: Evolution of patient's quality of life estimated with repeated measures of the Quality of Life in Alzheilmer's Disease scale, patient version
measure: Evolution of the patient's independence
time frame: 3 months and 6 months after randomization
description: Evolution of the patient's independence with repeated measures of the Instrumental Activities of Daily Life (IADL-E, 9 items).
measure: Evolution of the caregiver's quality of life
time frame: 3 months and 6 months after randomization
description: Evolution of the caregiver's quality of life estimated with repeated measures of the Quality of Life with EQ-5D questionnaire (EuroQol Five Dimensions questionnaire).
measure: Evolution of the patient's quality of life
time frame: 3 months and 6 months after randomization
description: Evolution of patient's quality of life estimated with repeated measures of the Quality of Life with EQ-5D questionnaire (EuroQol Five Dimensions questionnaire).
measure: Number of falls
time frame: 1 months, 3 months and 6 months after randomization
description: Number of times the patient has fallen after 1 month, 3 months and 6 months.
measure: Number of run aways
time frame: 1 months, 3 months and 6 months after randomization
description: Number of times the patient has ran away after 1 month, 3 months and 6 months.
measure: Number of drugs prescribed to the caregiver and the patient
time frame: at inclusion and at 6 months
description: Evolution of the number of drugs prescribed to the caregiver and the patient at inclusion and after 6 months of follow-up.
measure: Indirect medical costs and direct non-medical costs
time frame: 6 months
description: Data for indirect medical costs and direct non-medical costs will be collected with the RUD LITE questionnaire and the Lyon CMRR's MEMORA database
measure: Evaluation of the caregiver's adherence to the Lili Smart solution
time frame: 7 months
description: Evaluation of the caregiver's adherence to the Lili Smart solution after 7 months of follow-up (1 month of observation phase then 6 months of intervention) estimated through data collected in Lili Smart databases (number of connections to the application).
measure: Evaluation of patient's adherence to the Lili Smart solution
time frame: 7 months
description: Evaluation of the patient's adherence to the Lili Smart solution after 7 months of follow-up (1 month of observation phase then 6 months of intervention) estimated through data collected in Lili Smart databases (number of hours when the watch is worn).
measure: Caregiver's burden evolution
time frame: 3 months after randomization
description: Natural caregiver's burden evolution after 3 months of follow-up. Assessement with the Zarit scale
arm group label: Functionalities of the Lili Smart Solution activated
arm group type: Experimental
description: Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
arm group label: Functionalities of the Lili Smart Solution non activated
arm group type: Other
description: Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
intervention type: Other
intervention name: Functionalities of the Lili Smart Solution activated
description: Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
arm group label: Functionalities of the Lili Smart Solution activated
other name: Non-medical connected device (Lili Smart solution) with active functionalities
intervention type: Other
intervention name: Functionalities of the Lili Smart Solution non activated
description: Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
arm group label: Functionalities of the Lili Smart Solution non activated
other name: Non-medical connected device (Lili Smart solution) with inactive functionalities
criteria: 
gender: All
minimum age: 50 Years
maximum age: N/A
healthy volunteers: No
last name: Pierre Krolak-Salmon, MD
role: Principal Investigator
affiliation: Hospices Civils de Lyon
last name: Deborah Viricel
phone: 4 72 43 25 01
phone ext: +33
email: deborah.viricel@chu-lyon.fr
last name: Romain Bachelet
phone: 4 72 43 22 25
phone ext: +33
email: romain.bachelet@chu-lyon.fr
facility: 
status: Recruiting
contact: 
country: France
responsible party type: Sponsor
mesh term: Alzheimer Disease
mesh term: Pharmaceutical Solutions